Form 8-K - Current report:
SEC Accession No. 0001140361-23-000340
Filing Date
2023-01-04
Accepted
2023-01-04 08:35:31
Documents
14
Period of Report
2022-12-29
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K brhc10046238_8k.htm   iXBRL 8-K 63753
2 EXHIBIT 10.1 brhc10046238_ex10-1.htm EX-10.1 35467
6 image01.jpg GRAPHIC 2426
  Complete submission text file 0001140361-23-000340.txt   259054

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA erna-20221229.xsd EX-101.SCH 3866
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE erna-20221229_lab.xml EX-101.LAB 22547
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE erna-20221229_pre.xml EX-101.PRE 16045
8 EXTRACTED XBRL INSTANCE DOCUMENT brhc10046238_8k_htm.xml XML 4233
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (212) 582-1199
Eterna Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 23504457
SIC: 2834 Pharmaceutical Preparations